Abbott announced FDA clearances for two components of the company’s life support system.The CentriMag blood pump is now indicated for use with the CentriMag system for longer-term use in adults requiring extracorporeal membrane oxygenation (ECMO), allowing more time to assess next steps in the care for critically ill patients, according to a company release.
Abbott (NYSE: ABT) today announced two new clearances from the U.S. Food and Drug Administration (FDA) for the company's industry-leading life support system. With the new indication, the CentriMag Blood Pump for use with the CentriMag™ System, is now cleared for longer-term use in adults when extracorporeal .